Dianxing Hu, Ensong Guo, Bin Yang, Xu Qin, Yu Fu, Junpeng Fan, Xucui Zhuang, Qianqian Yao, Funian Lu, Wenting Li, Rourou Xiao, Xue Wu, Xiaohang Yang, Zizhuo Wang, Chen Liu, Lixin You, Rongyu Zang, Qi Zhou, Weidong Zhao, Gang Chen, Chaoyang Sun
Although resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) has gradually become a major challenge in the maintenance therapy for high-grade serous ovarian carcinoma (HGSOC), there are no universal indicators for resistance monitoring in patients. A key resistance mechanism to PARPi is the restoration of homologous recombination repair (HRR), including BRCA reversion mutations and changes in DNA damage repair proteins. To explore mutation profiles associated with PARPi resistance, we undertook targeted 42-gene deep sequencing of circulating cell-free DNA (cfDNA) extracted from HGSOC patients pre- and post-treatment with olaparib maintenance therapy...
August 2022: Cancer Science